TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07184385: A Multicenter, Double-blind, Randomized, Placebo-controlled, Two-arm Phase III Study to Assess the Efficacy of Human Umbilical Cord Blood (REGENECYTE) Infusion in Reducing Fatigue in Post-COVID Condition

Sponsor: StemCyte, Inc. · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 60 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$13,359,360

Rescue Site Savings

+$8,808,828

Unlock Full NCT07184385 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07184385 Rescue Dossier →